The field of cancer diagnosis and treatment has witnessed significant advancements with the emergence of liquid biopsies, particularly the analysis of circulating cell-free tumor DNA (cfDNA). Circulating cell-free tumor DNA refers to fragments of tumor-derived DNA that circulate in the bloodstream, offering valuable insights into the genomic profile of cancerous tumors. The circulating cell-free tumor DNA market encompasses various aspects, including technology advancements, diagnostic ... Read more

Market Overview:
Circulating cell-free tumor DNA (ctDNA) refers to fragments of tumor DNA that are released by cancer cells into the bloodstream. ctDNA provides a non-invasive means of monitoring tumor changes and guiding personalized treatment strategies. The detection of ctDNA is useful for cancer screening, diagnostics, treatment monitoring and recurrence monitoring.

The circulating cell-free tumor DNA market is estimated to be valued at US$ 6.1 Bn ... Read more